Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents

By                                  

Oncology Letters, Vol. 2, Iss. 1, 2011-01 ,pp. : 69-73

Spandidos Publications

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

VEGF, flt-1, and KDR/flk-1 as Prognostic Indicators in Endometrial Carcinoma

By Fine B.A.   Valente P.T.   Feinstein G.I.   Dey T.  

Gynecologic Oncology, Vol. 76, Iss. 1, 2000-01 ,pp. : 33-39

Elsevier

Access to resources Recommend Favorite

Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 163-170

Spandidos Publications

Access to resources Recommend Favorite

Mechanism of action of anti-HER2 monoclonal antibodies

By Baselga J.   Albanell J.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 35-41

Springer Publishing Company

Access to resources Recommend Favorite